Interferon Beta and Glatiramer Acetate Therapy

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

(2012) G Giovannoni et al.   Multiple Sclerosis Journal

The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis - Clinical Outcomes (PL02.003)

(2012) F. Lublin et al.   NEUROLOGY

Survival in MS

(2012) D.S. Goodin et al.   NEUROLOGY

Serum IL-17F does not predict poor response to IM IFN -1a in relapsing-remitting MS

(2012) S. E. Bushnell et al.   NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

(2011) Bernd C. Kieseier   CNS DRUGS

Glatiramer Acetate in the Treatment of Multiple Sclerosis

(2011) Patrice H. Lalive et al.   CNS DRUGS

Anaphylactic Reaction after Injection of Glatiramer Acetate (Copaxone®) in Patients with Relapsing-Remitting Multiple Sclerosis

(2011) Annette Baumgartner et al.   EUROPEAN NEUROLOGY

Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies

(2011) Brian Healy et al.   JOURNAL OF NEUROLOGY

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation

(2011) Harald Hegen et al.   Multiple Sclerosis Journal

Determinants of interferon β efficacy in patients with multiple sclerosis

(2011) Joep Killestein et al.   Nature Reviews Neurology

Overlapping and distinct mechanisms of action of multiple sclerosis therapies

(2010) J.J. Graber et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Glatiramer Acetate

(2010) Natalie J. Carter et al.   DRUGS

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

(2010) G. C. Ebers et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

(2010) Mads Ravnborg et al.   LANCET NEUROLOGY

Combination therapy in multiple sclerosis

(2010) Devon Conway et al.   LANCET NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

(2010) Maria Pia Sormani et al.   Multiple Sclerosis Journal

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis

(2009) Sandra R. Mirandola et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Concepts of induction and escalation therapy in multiple sclerosis

(2009) Peter Rieckmann   JOURNAL OF THE NEUROLOGICAL SCIENCES

Glatiramer acetate treatment in PPMS: Why males appear to respond favorably

(2009) Jerry S. Wolinsky et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial

(2009) Per Soelberg Sorensen et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

The challenge of follow-on biologics for treatment of multiple sclerosis

(2009) S. C. Reingold et al.   NEUROLOGY

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

(2009) J. A. Cohen et al.   NEUROLOGY

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate

(2009) V. Skihar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis

(2008) Annie W. Chiu   ARCHIVES OF NEUROLOGY

Glatiramer Acetate

(2008) François Blanchette et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

(2008) ALK Hestvik et al.   Multiple Sclerosis Journal

The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis

(2008) N De Stefano et al.   Multiple Sclerosis Journal

Disability as an outcome in MS clinical trials

(2008) G. C. Ebers et al.   NEUROLOGY